Telomir Pharmaceuticals (TELO) Institutional Ownership $1.57 -0.03 (-1.88%) Closing price 04:00 PM EasternExtended Trading$1.55 -0.02 (-1.27%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Telomir Pharmaceuticals (NASDAQ:TELO)Number ofInstitutional Buyers(last 12 months)23TotalInstitutional Inflows(last 12 months)$4.10MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$408.35K Get TELO Insider Trade Alerts Want to know when executives and insiders are buying or selling Telomir Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data TELO Institutional Buying and Selling by Quarter Telomir Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025Qube Research & Technologies Ltd26,509$33K0.0%N/A0.089% 8/13/2025Marshall Wace LLP75,770$95K0.0%N/A0.255% 8/8/2025 Geode Capital Management LLC196,880$246K0.0%-54.1%0.662% 8/1/2025 Y Intercept Hong Kong Ltd64,423$81K0.0%N/A0.216% 6/27/2025Goldman Sachs Group Inc.32,282$104K0.0%-36.1%0.108% 5/16/2025Goldman Sachs Group Inc.32,282$104K0.0%-36.1%0.108% 5/13/2025 HighTower Advisors LLC43,000$139K0.0%N/A0.144% 5/12/2025 Nuveen LLC24,990$81K0.0%N/A0.084% 4/29/2025 Bank of New York Mellon Corp91,353$295K0.0%+26.4%0.307% 2/17/2025Nuveen Asset Management LLC24,990$103K0.0%N/A0.084% Get the Latest News and Ratings for TELO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.10,699$44K0.0%+279.4%0.036% 2/17/2025Gotham Asset Management LLC6,770$28K0.0%N/A0.023% 2/17/2025Bank of America Corp DE14,713$61K0.0%+283.9%0.049% 2/14/2025Northern Trust Corp151,628$625K0.0%+211.5%0.510% 2/14/2025Transce3nd LLC28,803$119K0.0%N/A0.097% 2/13/2025Barclays PLC29,959$123K0.0%+326.9%0.101% 2/13/2025Wells Fargo & Company MN10,044$41K0.0%+458.3%0.034% 2/12/2025 Geode Capital Management LLC413,677$1.71M0.0%+73.3%1.390% 2/12/2025 JPMorgan Chase & Co.41,444$171K0.0%+1,096.4%0.139% 2/11/2025 Corebridge Financial Inc.9,613$40K0.0%+273.8%0.032% 2/11/2025 Virtu Financial LLC14,959$62K0.0%N/A0.050% 2/6/2025 Charles Schwab Investment Management Inc.46,406$191K0.0%+327.7%0.157% 2/4/2025 Bank of New York Mellon Corp72,295$298K0.0%+40.8%0.244% 1/30/2025 Rhumbline Advisers8,600$35K0.0%+105.9%0.029% 11/19/2024Barclays PLC7,018$45K0.0%+325.1%0.024% 11/16/2024 Geode Capital Management LLC238,737$1.53M0.0%+259.8%0.806% 11/15/2024Barclays PLC7,018$45K0.0%+325.1%0.024% 11/15/2024State Street Corp36,094$232K0.0%+99.1%0.122% 10/21/2024 Suncoast Equity Management51,194$329K0.0%+109.9%0.173% 8/15/2024Beaird Harris Wealth Management LLC14,623$70K0.0%+212.9%0.049% 7/26/2024 Bank of New York Mellon Corp50,165$241K0.0%N/A0.169% 5/2/2024 Suncoast Equity Management24,391$126K0.0%N/A0.082% (Data available from 1/1/2016 forward) TELO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of TELO shares? During the previous two years, 24 institutional investors and hedge funds held shares of Telomir Pharmaceuticals. The most heavily invested institutionals were Northern Trust Corp ($625K), Suncoast Equity Management ($329K), Bank of New York Mellon Corp ($295K), Geode Capital Management LLC ($246K), State Street Corp ($232K), Charles Schwab Investment Management Inc. ($191K), and JPMorgan Chase & Co. ($171K).Learn more on Telomir Pharmaceuticals' institutional investors. Which institutional investors have been buying Telomir Pharmaceuticals' stock? Of the 23 institutional investors that purchased Telomir Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Geode Capital Management LLC ($347.32K), Northern Trust Corp ($102.95K), Bank of New York Mellon Corp ($90.15K), Marshall Wace LLP ($75.77K), Y Intercept Hong Kong Ltd ($64.42K), Suncoast Equity Management ($51.19K), and HighTower Advisors LLC ($43K). How much institutional buying is happening at Telomir Pharmaceuticals? Institutional investors have bought a total of 1,000,873 shares in the last 24 months. This purchase volume represents approximately $4.10M in transactions. Which of Telomir Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold Telomir Pharmaceuticals stock in the last 24 months: Geode Capital Management LLC ($232.37K), and Goldman Sachs Group Inc. ($36.50K). How much institutional selling is happening at Telomir Pharmaceuticals? Institutional investors have sold a total of 268,868 shares in the last 24 months. This volume of shares sold represents approximately $408.35K in transactions. Related Companies ProQR Therapeutics Major Shareholders Editas Medicine Major Shareholders Larimar Therapeutics Major Shareholders CARGO Therapeutics Major Shareholders Aerovate Therapeutics Major Shareholders MediWound Major Shareholders Caribou Biosciences Major Shareholders enGene Major Shareholders Eledon Pharmaceuticals Major Shareholders Innate Pharma Major Shareholders This page (NASDAQ:TELO) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.